Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Amylyx Pharmaceuticals Inc (AMLX)

Amylyx Pharmaceuticals Inc (AMLX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,567,420
  • Shares Outstanding, K 66,256
  • Annual Sales, $ 290 K
  • Annual Income, $ -87,930 K
  • 60-Month Beta N/A
  • Price/Sales 8,729.52
  • Price/Cash Flow N/A
  • Price/Book 17.27
Trade AMLX with:

Options Overview Details

View History
  • Implied Volatility 66.88% ( +0.74%)
  • Historical Volatility 42.49%
  • IV Percentile 2%
  • IV Rank 1.12%
  • IV High 312.30% on 06/02/22
  • IV Low 64.11% on 11/18/22
  • Put/Call Vol Ratio 0.03
  • Today's Volume 420
  • Volume Avg (30-Day) 573
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 0
  • Open Int (30-Day) 44,491

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -0.76
  • Number of Estimates 2
  • High Estimate -0.72
  • Low Estimate -0.80
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.08%

Price Performance

See More
Period Period Low Period High Performance
1-Month
32.69 +18.54%
on 11/07/22
39.08 -0.83%
on 11/25/22
+1.35 (+3.61%)
since 10/25/22
3-Month
15.80 +145.25%
on 09/02/22
39.08 -0.83%
on 11/25/22
+12.29 (+46.45%)
since 08/25/22

Most Recent Stories

More News
Amylyx Pharmaceuticals to Participate in the Evercore ISI 5th Annual HealthCONx Conference

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) today announced that Joshua Cohen and Justin Klee, Co-CEOs of Amylyx, will participate in the Evercore ISI 5th Annual HealthCONx Conference. The conference is...

AMLX : 38.75 (+3.20%)
Amylyx Pharmaceuticals Reports Third Quarter 2022 Financial Results

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today reported financial results for the quarter ended September 30, 2022.

AMLX : 38.75 (+3.20%)
Amylyx Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 10, 2022

Amylyx Pharmaceuticals, Inc. (“Amylyx”) today announced it will report third quarter 2022 financial results on Thursday, November 10, 2022 following the close of the U.S. financial markets. Amylyx’...

AMLX : 38.75 (+3.20%)
NeuroSense Therapeutics Provides CEO's Q3 Update and Nasdaq Opening Bell Ceremony Remarks Video

/PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today...

AMLX : 38.75 (+3.20%)
NRSN : 1.7500 (-1.13%)
Amylyx Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Amylyx Pharmaceuticals, Inc. (“Amylyx”) today announced the closing of its previously announced upsized underwritten public offering of 7,697,812 shares of its common stock at a public offering price...

AMLX : 38.75 (+3.20%)
Amylyx Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

Amylyx Pharmaceuticals, Inc. (“Amylyx”) today announced the pricing of an upsized underwritten public offering of 6,693,750 shares of its common stock at a public offering price of $32.00 per share....

AMLX : 38.75 (+3.20%)
Amylyx Pharmaceuticals Announces Launch of Public Offering

Amylyx Pharmaceuticals, Inc. (“Amylyx”) today announced the launch of an underwritten public offering of 6,000,000 shares of common stock pursuant to a registration statement on Form S-1 filed with...

AMLX : 38.75 (+3.20%)
Stocks Surge on Lower T-note Yields and a Rally in Energy Stocks

What you need to know… The S&P 500 Index ($SPX ) (SPY ) on Monday closed up +2.59%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +2.66%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up...

$SPX : 4,026.12 (-0.03%)
SPY : 402.33 (-0.02%)
$DOWI : 34,347.03 (+0.45%)
DIA : 343.52 (+0.46%)
$IUXX : 11,756.03 (-0.70%)
QQQ : 286.92 (-0.66%)
APA : 46.43 (-0.75%)
DVN : 68.35 (+0.81%)
FANG : 149.32 (-0.45%)
COP : 126.81 (+0.06%)
HAL : 36.36 (-0.55%)
HES : 144.76 (-0.10%)
Stocks Soar as Weak U.S. Economic News Pushes T-note Yields Lower

What you need to know… The S&P 500 Index ($SPX ) (SPY ) this morning is up +1.65%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +1.86%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.10%....

$SPX : 4,026.12 (-0.03%)
SPY : 402.33 (-0.02%)
$DOWI : 34,347.03 (+0.45%)
DIA : 343.52 (+0.46%)
$IUXX : 11,756.03 (-0.70%)
QQQ : 286.92 (-0.66%)
DVN : 68.35 (+0.81%)
FANG : 149.32 (-0.45%)
HAL : 36.36 (-0.55%)
COP : 126.81 (+0.06%)
APA : 46.43 (-0.75%)
SLB : 50.83 (-1.15%)
Markets Today: Stocks Rise on Strength in Energy Stocks and Lower Bond Yields

Morning Markets December S&P 500 futures (ESZ22 ) this morning are up by +0.63%. Stock index futures shook off overnight losses after a jump of more than +4% in crude oil price sparked a rally in energy...

ESZ22 : 4,006.50 (-0.64%)
CVX : 183.70 (-0.29%)
COP : 126.81 (+0.06%)
DVN : 68.35 (+0.81%)
FANG : 149.32 (-0.45%)
XOM : 113.21 (-0.35%)
HAL : 36.36 (-0.55%)
SLB : 50.83 (-1.15%)
VLO : 138.40 (-0.58%)
SWN : 7.16 (-0.83%)
AMLX : 38.75 (+3.20%)
CF : 108.62 (+2.17%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Business Summary

Amylyx Pharmaceuticals Inc. is a clinical-stage pharmaceutical company. It focuses on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. Amylyx Pharmaceuticals Inc. is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 42.77
2nd Resistance Point 40.92
1st Resistance Point 39.84
Last Price 38.75
1st Support Level 36.90
2nd Support Level 35.05
3rd Support Level 33.96

See More

52-Week High 39.08
Last Price 38.75
Fibonacci 61.8% 26.64
Fibonacci 50% 22.79
Fibonacci 38.2% 18.95
52-Week Low 6.51

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar